Episode 25026
No More Transfusions!!! Dr. John Scarlett, President and CEO of Geron Corporation
BioTech Nation ... with Dr. Moira Gunn · Moira Gunn
July 9, 202516m 10s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval.
Topics
blood transfusionmyelodysplastic syndrome (MDS)Imetelstattelomerase inhibitorGeron Corporationphase three trialstransfusion dependencecancer cellsbone marrowPDUFA dateresearch and development